FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127572783> ?p ?o ?g. }

• W2127572783 endingPage "1205" @default.
• W2127572783 startingPage "1195" @default.
• W2127572783 abstract "Inflammation and neurodegeneration may have differential impacts on disease evolution in the different forms of multiple sclerosis. However, a beneficial effect of immunomodulatory drugs should not be ruled out in primary progressive multiple sclerosis. Our aim is to investigate the safety and efficacy of interferon beta-1b in primary progressive multiple sclerosis. We conducted a double-blind, stratified, randomized, parallel group, phase II pilot study where patients with primary progressive multiple sclerosis or ‘transitional’ forms of multiple sclerosis received interferon beta-1b at doses of 8 MIU or placebo for 24 months. The main objective of the study was to investigate the safety and tolerability of interferon beta-1b. The primary efficacy variable was the time to neurological deterioration (Expanded Disability Status Scale) confirmed at 3 months. Seventy-three patients were included and three dropped out the study. More patients in the treatment arm had at least one related adverse event (94.4% versus 45.9%; p < 0.001); no other significant differences in safety endpoints were observed. Time to neurological deterioration was not different between trial arms (log-rank test, p = 0.3135). Statistically significant differences favoring treatment were observed for the Multiple Sclerosis Functional Composite score at several timepoints, T1 and T2 lesion volume changes at 12 and 24 months, mean number of active lesions and proportion of patients with active lesions at 24 months. We conclude that interferon beta-1b is safe and well tolerated in patients with primary progressive multiple sclerosis and transitional multiple sclerosis. Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated." @default.
• W2127572783 created "2016-06-24" @default.
• W2127572783 creator A5002514823 @default.
• W2127572783 creator A5004845040 @default.
• W2127572783 creator A5018150387 @default.
• W2127572783 creator A5031171090 @default.
• W2127572783 creator A5045203220 @default.
• W2127572783 creator A5063275381 @default.
• W2127572783 creator A5066657786 @default.
• W2127572783 creator A5074577405 @default.
• W2127572783 creator A5075497872 @default.
• W2127572783 creator A5079962370 @default.
• W2127572783 date "2009-09-29" @default.
• W2127572783 modified "2023-10-18" @default.
• W2127572783 title "A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis" @default.
• W2127572783 cites W1937911740 @default.
• W2127572783 cites W1980788749 @default.
• W2127572783 cites W1983810376 @default.
• W2127572783 cites W1990040006 @default.
• W2127572783 cites W1991343124 @default.
• W2127572783 cites W1995004187 @default.
• W2127572783 cites W1997824576 @default.
• W2127572783 cites W2005506388 @default.
• W2127572783 cites W2005623950 @default.
• W2127572783 cites W2028174673 @default.
• W2127572783 cites W2038428996 @default.
• W2127572783 cites W2040430789 @default.
• W2127572783 cites W2046941822 @default.
• W2127572783 cites W2047062145 @default.
• W2127572783 cites W2049808343 @default.
• W2127572783 cites W2056736742 @default.
• W2127572783 cites W2060928628 @default.
• W2127572783 cites W2064687595 @default.
• W2127572783 cites W2067495470 @default.
• W2127572783 cites W2073553957 @default.
• W2127572783 cites W2079781144 @default.
• W2127572783 cites W2087589796 @default.
• W2127572783 cites W2090095728 @default.
• W2127572783 cites W2097669496 @default.
• W2127572783 cites W2099467824 @default.
• W2127572783 cites W2104977064 @default.
• W2127572783 cites W2112264084 @default.
• W2127572783 cites W2131606060 @default.
• W2127572783 cites W2146802292 @default.
• W2127572783 cites W2146853725 @default.
• W2127572783 cites W2147062889 @default.
• W2127572783 cites W2147552627 @default.
• W2127572783 cites W2160727196 @default.
• W2127572783 cites W2165547142 @default.
• W2127572783 cites W2189829250 @default.
• W2127572783 cites W2312952586 @default.
• W2127572783 cites W2326826867 @default.
• W2127572783 cites W2574627421 @default.
• W2127572783 cites W4210933644 @default.
• W2127572783 cites W4243836282 @default.
• W2127572783 doi "https://doi.org/10.1177/1352458509106937" @default.
• W2127572783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19797261" @default.
• W2127572783 hasPublicationYear "2009" @default.
• W2127572783 type Work @default.
• W2127572783 sameAs 2127572783 @default.
• W2127572783 citedByCount "90" @default.
• W2127572783 countsByYear W21275727832012 @default.
• W2127572783 countsByYear W21275727832013 @default.
• W2127572783 countsByYear W21275727832014 @default.
• W2127572783 countsByYear W21275727832015 @default.
• W2127572783 countsByYear W21275727832016 @default.
• W2127572783 countsByYear W21275727832017 @default.
• W2127572783 countsByYear W21275727832018 @default.
• W2127572783 countsByYear W21275727832019 @default.
• W2127572783 countsByYear W21275727832020 @default.
• W2127572783 countsByYear W21275727832021 @default.
• W2127572783 countsByYear W21275727832022 @default.
• W2127572783 countsByYear W21275727832023 @default.
• W2127572783 crossrefType "journal-article" @default.
• W2127572783 hasAuthorship W2127572783A5002514823 @default.
• W2127572783 hasAuthorship W2127572783A5004845040 @default.
• W2127572783 hasAuthorship W2127572783A5018150387 @default.
• W2127572783 hasAuthorship W2127572783A5031171090 @default.
• W2127572783 hasAuthorship W2127572783A5045203220 @default.
• W2127572783 hasAuthorship W2127572783A5063275381 @default.
• W2127572783 hasAuthorship W2127572783A5066657786 @default.
• W2127572783 hasAuthorship W2127572783A5074577405 @default.
• W2127572783 hasAuthorship W2127572783A5075497872 @default.
• W2127572783 hasAuthorship W2127572783A5079962370 @default.
• W2127572783 hasConcept C126322002 @default.
• W2127572783 hasConcept C142724271 @default.
• W2127572783 hasConcept C197934379 @default.
• W2127572783 hasConcept C203014093 @default.
• W2127572783 hasConcept C203092338 @default.
• W2127572783 hasConcept C204787440 @default.
• W2127572783 hasConcept C27081682 @default.
• W2127572783 hasConcept C2778375690 @default.
• W2127572783 hasConcept C2778577042 @default.
• W2127572783 hasConcept C2780640218 @default.
• W2127572783 hasConcept C2780892749 @default.
• W2127572783 hasConcept C2908698914 @default.
• W2127572783 hasConcept C2910198813 @default.
• W2127572783 hasConcept C2994247566 @default.

• next